To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Alnylam Pharmaceuticals Announces the Termination of its RNAi Collaboration with Merck
Alnylam Pharmaceuticals, has announced that Merck & Co., Inc. ("Merck") and Alnylam have mutually agreed to terminate their July 2006 amended and restated RNAi agreement.
As a result, Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership's former co-development programs.
"It is fundamentally in our best interests to terminate our Merck collaboration," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. "We wish our colleagues at Merck the best of luck in their efforts."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
